Clinical and Translational Oncology

, Volume 9, Issue 5, pp 298–307 | Cite as

Oxycodone: a pharmacological and clinical review

  • A. Ordóñez GallegoEmail author
  • M. González Barón
  • E. Espinosa Arranz


Oxycodone is a semi-synthetic opioid with an agonist activity on mu, kappa and delta receptors. Equivalence with regard to morphine is 1:2. Its effect commences one hour after administration and lasts for 12 h in the controlled-release formulation. Plasma half-life is 3–5 h (half that of morphine) and stable plasma levels are reached within 24 h (2–7 days for morphine). Oral bioavailability ranges from 60 to 87%, and plasma protein binding is 45%. Most of the drug is metabolised in the liver, while the rest is excreted by the kidney along with its metabolites. The two main metabolites are oxymorphone — which is also a very potent analgesic — and noroxycodone, a weak analgesic. Oxycodone metabolism is more predictable than that of morphine, and therefore titration is easier. Oxycodone has the same mechanism of action as other opioids: binding to a receptor, inhibition of adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability. These mechanisms also play a part in the onset of dependence and tolerance. The clinical efficacy of oxycodone is similar to that of morphine, with a ratio of 1/1.5–2 for the treatment of cancer pain. Long-term administration may be associated with less toxicity in comparison with morphine. In the future, both opioids could be used simultaneously at low doses to reduce toxicity. It does not appear that there are any differences between immediate and slow-release oxycodone, except their half-life is 3–4 h, and 12 h, respectively. In Spain, controlled-release oxycodone (OxyContin®) is marketed as 10-, 20-, 40-or 80-mg tablets for b.i.d. administration. Tablets must be taken whole and must not be broken, chewed or crushed. There is no food interference. The initial dose is 10 mg b.i.d. for new treatments and no dose reduction is needed in the elderly or in cases of moderate hepatic or renal failure. Immediate-release oxycodone (OxyNorm®) is also available in capsules and oral solution. Side effects are those common to opioids: mainly nausea, constipation and drowsiness. Vomiting, pruritus and dizziness are less common. The intensity of these side effects tends to decrease over the course of time. Oxycodone causes somewhat less nausea, hallucinations and pruritus than morphine.

Key words

Oxycodone Opioid Pain 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cassinello J (2004) El dolor. Definición, tipos patogénicos, formas de presentación y evaluación del dolor. In Camps C (eds) Manual SEOM de Cuidados Continuos. Dispublic, S.L., MadridGoogle Scholar
  2. 2.
    González Barón M, Ordóñez Gallego A (2003) Dolor y cáncer. Editorial Médica Panamericana, MadridGoogle Scholar
  3. 3.
    González Barón M, Ordóñez Gallego A (2000) Dolor oncológico. Sentido del sufrimiento. In Ortiz JS (ed.) El control del sufrimiento evitable. Terapia analgésica. You and Us, S.A., MadridGoogle Scholar
  4. 4.
    Ordóñez Gallego A, González Barón M (2004) Oxicodona: nuevo opioide. Revista de Oncología 6:203–206Google Scholar
  5. 5.
    Domínguez G, Gómez Sancho M, Verd M, Brennan LD (2004) Oxicodona, una opción en el manejo del dolor desde 1917. Medicina Paliativa 11:246–263Google Scholar
  6. 6.
    Ordóñez A, González Barón M, Feliu J et al (2001) Tratamiento de soporte en el enfermo con cáncer. Algunas propuestas basadas en nuestra experiencia. Revista de Oncología 3:266–269Google Scholar
  7. 7.
    Ordóñez A, De Castro J, Espinosa E et al (2003) Transdermal fentanyl treatment in opioid-naïve cancer patients. Revista de Oncología 5:162–165Google Scholar
  8. 8.
    Escudero P, Ordóñez A, Cassinello J (2003) Initial doses of fentanyl-TTS based on pain intensity with cancer pain. Thirty-Ninth Annual Meeting ASCO, Chicago, abst. 3123Google Scholar
  9. 9.
    Poyhia R, Vainio A, Kalso E (1993) A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8:63–67PubMedCrossRefGoogle Scholar
  10. 10.
    Sacerdote P, Manfredi B, Mantegazza P, Panerai AE (1997) Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 121:834–840PubMedCrossRefGoogle Scholar
  11. 11.
    Ross FB, Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear to be k-opioid receptor mediated. Pain 73:151–157PubMedCrossRefGoogle Scholar
  12. 12.
    Smith MT, Ross FB, Nielsen CK, Saini K (2001) Oxycodone has a distinctly different pharmacology from morphine. Eur J Pain 5[Suppl A]:135–136CrossRefGoogle Scholar
  13. 13.
    Varga J, Dickerson ED, Davis MP (2001) United States prescribing habits: what’s going on? (abstract) Support Care Cancer 9:311Google Scholar
  14. 14.
    Falk E (1917) Eukodal, ein neues narkotikum. Munch Med Wochenschr 20:381–384Google Scholar
  15. 15.
    Inturrisi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18:S3–S13PubMedCrossRefGoogle Scholar
  16. 16.
    Levy MH (2001) Advancement of opioid analgesia with controlled-release oxycodone. Eur J Pain 5[Suppl A]:113–116PubMedCrossRefGoogle Scholar
  17. 17.
    Evans PJD (1999) Controlled-release oxycodone: do we need another opiate analgesic? Eur J Pain 3:67–68CrossRefGoogle Scholar
  18. 18.
    Colucci RD, Swanton RE, Gordon ThB, Kaiko RF (2001) Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine. Am J Ther 8:231–236PubMedCrossRefGoogle Scholar
  19. 19.
    Benziger DP, Kaiko RF, Miotto JB et al (1996) Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. J Pharm Sci 85:407–410PubMedCrossRefGoogle Scholar
  20. 20.
    Davis M, Wilcock A (2001) Modified-release opioids. Eur J Palliat Care 8:142–146Google Scholar
  21. 21.
    Heiskanen T, Olkkola KT, Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64:603–611PubMedCrossRefGoogle Scholar
  22. 22.
    Leow KP, Cramond T, Smith MT (1995) Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 80:296–302PubMedCrossRefGoogle Scholar
  23. 23.
    Kaiko RF, Benzinger DP, Fitzmartin RD et al (1996) Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 59:52–61PubMedCrossRefGoogle Scholar
  24. 24.
    Davis MP, Varga J, Dickerson D et al (2003) Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 11:84–92PubMedGoogle Scholar
  25. 25.
    Poyhia R, Seppala T, Oikkola KT, Kalso E (1992) The pharmacokinetics and metabolism of oxycodone alter intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33:617–621PubMedGoogle Scholar
  26. 26.
    Flórez J, Reig E (1993) Terapéutica farmacológica del dolor. Ediciones Universidad de Navarra S.A., PamplonaGoogle Scholar
  27. 27.
    Belda C, Fresno JA, Ceja P, González Barón M (2003) Bases moleculares de la respuesta a los opioides. In Ordóñez Gallego A, González Barón M (eds) Dolor y cáncer. Hacia una oncología sin dolor. Editorial Médica Panamericana S.A., MadridGoogle Scholar
  28. 28.
    Watson PN, Babul N (1998) Efficacy of oxycodone in neuropathic pain a randomized trial in postherpetic neuralgia. Neurology 58:1837–1841Google Scholar
  29. 29.
    Hale ME, Fleischman R, Salzman R et al (1999) Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 15:179–183PubMedCrossRefGoogle Scholar
  30. 30.
    Kampe S, Warm S, Kaufmann J et al (2004) Clinical efficacy of controlled-release oxycodone 20 mg administered on a 12-h dosing schedule on the management of postoperative pain after breast surgery for cancer. Curr Med Res Opin 20:199–202PubMedCrossRefGoogle Scholar
  31. 31.
    Hagen N, Babul N (1997) Comparative clinical efficacy and safety of a novel controlled release oxycodone formulation and controlled release hydromorphone in the treatment of cancer pain. Cancer 79:1428–1437PubMedCrossRefGoogle Scholar
  32. 32.
    Heiskanen T, Kalso E (1997) Controlled-release oxycodone and morphine in cancer related pain. Pain 73:37–45PubMedCrossRefGoogle Scholar
  33. 33.
    Citron M, Kaplan R, Parris W et al (1998) Long-term administration of controlled release oxycodone tablets for the treatment of cancer pain. Cancer Invest 16:562–571PubMedGoogle Scholar
  34. 34.
    Mucci-LeRusso P, Berman BS, Silberstein PT et al (1998) Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double blind, parallel-group study. Eur J Pain 2:239–249CrossRefGoogle Scholar
  35. 35.
    Bruera E, Belzile M, Pituskin E (1998) Randomized, double blind cross over trial comparing safety and efficacy of oral controlled release oxycodone with controlled release morphine in patients with cancer pain. J Clin Oncol 16:3222–3229PubMedGoogle Scholar
  36. 36.
    Kaplan R, Parris W, Citron M et al (1998) Comparison of controlled-release and immediate release oxycodone tablets in patients with cancer pain. J Clin Oncol 16:3230–3237PubMedGoogle Scholar
  37. 37.
    Parris W, Johnson B, Croghan M et al (1998) The use of controlled release oxycodone for the treatment of chronic cancer pain: a randomised, double-blind study. J Pain Symptom Manage 16:205–211PubMedCrossRefGoogle Scholar
  38. 38.
    Salzman R, Roberts M, Wild J et al (1999) Can a controlled release oral dose form of oxycodone be used as readily as an immediate release form for the purpose of titrating to stable pain control? J Pain Symptom Manage 18:271–279PubMedCrossRefGoogle Scholar
  39. 39.
    Stambaugh JE, Reder RF (2001) Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled-and immediate-release oral oxycodone in cancer pain patients. J Clin Pharmacol 41:500–506PubMedCrossRefGoogle Scholar
  40. 40.
    Lauretti GR, Oliveira GM, Pereira NL (2003) Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 89:2027–2030PubMedCrossRefGoogle Scholar
  41. 41.
    Ripamonti C, Dickerson D (2001) Strategies for the treatment of cancer pain in the New Millennium. Drugs 61:955–977PubMedCrossRefGoogle Scholar
  42. 42.
    Ross FB, Wallis SC, Smith MT (2000) Co-administration of sub-antinociceptive synergy with reduced CSN side-effects in rats. Pain 84:421–428PubMedCrossRefGoogle Scholar
  43. 43.
    Riley J, Ross J, Rutter D et al (2006) No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 14:56–64PubMedCrossRefGoogle Scholar
  44. 44.
    Watson CPN, Moulin D et al (2003) Controlledrelease oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105:71–78PubMedCrossRefGoogle Scholar
  45. 45.
    Gimbel J, Richards P, Portenoy RK (2003) Controlled-release oxycodone for pain in diabetic neuropathy. Neurology 60:894–895Google Scholar
  46. 46.
    Finnerup NB, Otto M, McQuay HJ et al (2005) Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118:289–305PubMedCrossRefGoogle Scholar
  47. 47.
    Wallsch TM (2002) Oxycodone retard in a patient suffering form a polyneuropathy with burning dysaesthesia. Neurol Rehabil 8:208–210Google Scholar
  48. 48.
    Roth SH et al (2000) Around the clock, controlled-release oxycodone therapy for osteoarthritis related pain. Placebo controlled trial and long term evaluation. Arch Intern Med 160:853–860PubMedCrossRefGoogle Scholar
  49. 49.
    Ytteberg SR, Mahowald ML, Woods SR (1998) Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum 41:1603–1612CrossRefGoogle Scholar
  50. 50.
    Caldwell JR, Hale ME, Boyd RE et al (1999) Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double-blind, randomized, multicenter, placebo controlled trial. J Rheumatol 26:862–869PubMedGoogle Scholar
  51. 51.
    McCroskery E, Croft J, Markenson J et al (2000) 3-month efficacy and safety study of OxyContin in osteoarthritis patients. Proceedings of EFIC, Sep 26–29, Nice, FranceGoogle Scholar
  52. 52.
    Markeson JA, Croft J, Zhang PG et al (1996) Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone. Br J Clin Pharmacol 42:747–756CrossRefGoogle Scholar
  53. 53.
    Zautra AJ, Bruce BW (2005) Impact of controlled-release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clin J Pain 21: 471–477PubMedCrossRefGoogle Scholar
  54. 54.
    Gammaitoni AR et al (2003) Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. Pain Med 4: 21–30PubMedCrossRefGoogle Scholar
  55. 55.
    Überall MA, Mueller-Schwefe G (2005) Untreated pain-optimizing multidisciplinary rehabilitation programs in high-risk patients with chronic low back pain using WHO-III opioid oxycodone. Abstracts, 11th World Congress on PainGoogle Scholar
  56. 56.
    Krämer J (2005) Effective and safe treatment of lumbar root compression syndrome with sustained-release oxycodone. Abstracts, 11th World Congress on PainGoogle Scholar
  57. 57.
    Reuben SS, Connelly NR, Maciolek H (1999) Postoperative analgesia with controlled-release oxycodone for outpatient anterior cruciate ligament surgery. Anesth Analg 88:1286–1291PubMedCrossRefGoogle Scholar
  58. 58.
    Cheville A, Chen A, Oster G et al (2001) A randomized trial of controlled-release oxycodone during inpatient rehabilitation following unilateral total knee arthroplasty. J Bone Joint Surg 83A:572–576Google Scholar
  59. 59.
    Wirz S et al (2005) Post-operative pain therapy with controlled release oxycodone or controlled release tramadol following orthopaedic surgery: a prospective, randomized, double-blind investigation. Pain Clin 17:367–376CrossRefGoogle Scholar
  60. 60.
    de Beer JdeV, Winemaker MJ, Donnelly GA et al (2005) Efficacy and safety of controlled-release oxycodone and standard therapies for postoperative pain after knee or hip replacement. Can J Surg 48: 277–283PubMedGoogle Scholar
  61. 61.
    Hohwü L, Akre O, Bergenwald L et al (2006) Oral oxycodone hydrochloride versus epidural anaesthesia for pain control after radical retropubic prostatectomy. Scand J Urol Nephrol 40:192–197PubMedCrossRefGoogle Scholar
  62. 62.
    Staal C, Drenes AM (2004) Experimental human pain models: a review standardised methods for preclinical testing of analgesics. Basic Clin Pharmacol Toxicol 95:97–111Google Scholar
  63. 63.
    Sorensen TR, Staal C, Arendt-Nielsen L et al (2006) Differential effects of opioids in patients with chronic pancreatitis. An experimental pain study. Digestive Disease Week, Los Angeles, USA, 2006. Poster no. 223486Google Scholar
  64. 64.
    Staal C, Christrup LL, Andersen SD et al (2006) A comparative study of oxycodone and morphine in a multimodal, tissue differentiated experimental pain model. Pain 123:28–36CrossRefGoogle Scholar
  65. 65.
    Bezinger D, Kaiko R, Mohito J et al (1996) Differential effects of food on the bioavailability of controlled release oxycodone tablets and immediate release oxycodone solution. J Pharm Sci 58:407–410Google Scholar
  66. 66.
    Borrás JL, Rodríguez D, Lafuerza A (2004) Manejo del dolor complejo. In Camps C (eds) Manual SEOM de Cuidados Continuos. Dispublic S.L., MadridGoogle Scholar
  67. 67.
    Vilches Y, De Luis V, González Barón M (2003) Rotación de opioides. In González Barón M, Ordóñez Gallego A (eds) Dolor y cáncer. Hacia una oncología sin dolor. Editorial Médica Panamericana S.A., MadridGoogle Scholar
  68. 68.
    Hanks GW, De Conno F, Cherny N et al (2002) Morfina y opiáceos alternativos para el tratamiento del dolor oncológico. Medicina Paliativa 9:22–29Google Scholar
  69. 69.
    Rischitelli G, Karbowicz SH (2002) Safety and efficacy of controlled-release oxycodone: a systematic literature review. Pharmacotherapy 22:898–904PubMedCrossRefGoogle Scholar
  70. 70.
    Maddocks I, Somogyi A, Abbott F et al (1996) Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 12:182–189PubMedCrossRefGoogle Scholar
  71. 71.
    Davis M, Tailcock A (2001) Modified-release opioids. Eur J Palliative Care 8:142–146Google Scholar
  72. 72.
    Ripamonti C, Bruera E (1997) CNS adverse effects of opioids in cancer patients. Guidelines for treatment. CNS Drugs 8:21–37Google Scholar
  73. 73.
    Saarialho-Kere U, Mattila MJ, Seppala T (1989) Psychomotor, respiratory and neuroendocrinological effects of a Mu-opioid receptor agonist (oxycodone) in healthy volunteers. Pharmacol Toxicol 65:252–257PubMedCrossRefGoogle Scholar

Copyright information

© Feseo 2007

Authors and Affiliations

  • A. Ordóñez Gallego
    • 1
    Email author
  • M. González Barón
    • 1
  • E. Espinosa Arranz
    • 1
  1. 1.Medical Oncology Service. “La Paz” University Hospital Madrid. Cátedra de Oncología y Medicina Paliativa.Universidad Autónoma de MadridMadridSpain

Personalised recommendations